The US FDA's Oncologic Drugs Advisory Committee will convene March 29 to assess the acceptability of Genentech Inc.’s pharmacokinetic bridging development program for its subcutaneously administered monoclonal antibody rituximab – a discussion that could have implications for biosimilars as well as the oncology market.
Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK
Genentech used pharmacokinetic bridging studies for new route of administration, which uses the enzyme hyaluronidase and is strongly preferred by patients over the IV; firm is seeking indications for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
More from US FDA Performance Tracker
More from Regulatory Trackers
• By
March features nearly 20 user fee goal dates, including a crowd of novel candidates for crowded areas like hemophilia, heart disease and urinary tract infections, as well as the potentially first therapies for a rare eye disease and hyperphagia of Prader-Willi syndrome.
• By
The European Medicines Agency is set to issue opinions this week on whether pan-EU marketing approval should be granted to a number of new products.
• By
The US FDA approval of new meningococcal and chikungunya vaccines arrived in time for the 26-28 February meeting of the CDC’s Advisory Committee On Immunization Practices, if political developments allow.